Global Equine Chorionic Gonadotropin (eCG) for Injection Market Growth 2024-2030

Global Equine Chorionic Gonadotropin (eCG) for Injection Market Growth 2024-2030

Equine chorionic gonadotropin (eCG), also known as pregnant mare serum gonadotropin (PMSG) or equine luteinizing hormone. Equine chorionic gonadotropin is a gonadotropic hormone produced in the chorion of pregnant mares. The action of eCG is similar to the action of Follicle- Stimulating Hormone (FSH), which is produced by the animals' anterior pituitary gland. It stimulates the follicles of the ovaries to produce mature ova (eggs), and it promotes the outward signs of estrus (heat).

The global Equine Chorionic Gonadotropin (eCG) for Injection market size is projected to grow from US$ 263 million in 2024 to US$ 352 million in 2030; it is expected to grow at a CAGR of 5.0% from 2024 to 2030.

LP Information, Inc. (LPI) ' newest research report, the “Equine Chorionic Gonadotropin (eCG) for Injection Industry Forecast” looks at past sales and reviews total world Equine Chorionic Gonadotropin (eCG) for Injection sales in 2023, providing a comprehensive analysis by region and market sector of projected Equine Chorionic Gonadotropin (eCG) for Injection sales for 2024 through 2030. With Equine Chorionic Gonadotropin (eCG) for Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Equine Chorionic Gonadotropin (eCG) for Injection industry.

This Insight Report provides a comprehensive analysis of the global Equine Chorionic Gonadotropin (eCG) for Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Equine Chorionic Gonadotropin (eCG) for Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Equine Chorionic Gonadotropin (eCG) for Injection market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Equine Chorionic Gonadotropin (eCG) for Injection and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Equine Chorionic Gonadotropin (eCG) for Injection.

United States market for Equine Chorionic Gonadotropin (eCG) for Injection is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Equine Chorionic Gonadotropin (eCG) for Injection is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Equine Chorionic Gonadotropin (eCG) for Injection is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Equine Chorionic Gonadotropin (eCG) for Injection players cover MSD Animal Health, Ceva Santé Animale, Syntex SA, Bioveta, Ningbo Sansheng Biological Technology, etc. In terms of revenue, the global two largest companies occupied for a share nearly

% in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Equine Chorionic Gonadotropin (eCG) for Injection market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
1000 IU/Unit
5000 IU/Unit
Others

Segmentation by Application:
Pig
Cattle
Sheep
Horse
Other Animals

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
MSD Animal Health
Ceva Santé Animale
Syntex SA
Bioveta
Ningbo Sansheng Biological Technology
Ningbo Second Hormone Factory
Chifeng Bo-en Pharmaceutical
Guangzhou Vbio-Pharma
JALLY
Ningbo Creator Animal Pharmaceutical

Key Questions Addressed in this Report

What is the 10-year outlook for the global Equine Chorionic Gonadotropin (eCG) for Injection market?

What factors are driving Equine Chorionic Gonadotropin (eCG) for Injection market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Equine Chorionic Gonadotropin (eCG) for Injection market opportunities vary by end market size?

How does Equine Chorionic Gonadotropin (eCG) for Injection break out by Type, by Application?



Please note: The report will take approximately 2 business days to prepare and deliver.